ASX healthcare shares have spent the past year being repriced harder than almost any other corner of the market.
CSL Ltd (ASX: CSL) fell as low as $90 before staging a recovery, and Pro Medicus Ltd (ASX: PME) has roughly halved from the high it set less than a year ago.
Yet the sector rose 9% in a week during reporting season, which tells you sentiment may have started to turn.
Image source: Getty Images
Why ASX healthcare shares fell so far
The damage was mostly self-inflicted at the company level.
CSL wrote down its Vifor acquisition, Pro Medicus derated from an extraordinary multiple, and drug pricing pressure from the United States hung over the entire sector.
None of those problems has vanished, but the price investors are now asked to pay for them has changed.
That is usually where the better opportunities in a beaten-up sector are found.
1. CSL
CSL trades around $175 against a 52-week range of $90.00 to $222.47.
FY26 was openly badged as a reset year.
Revenue slipped 1% to US$15.8 billion, and impairments of US$7.1 billion drove a statutory loss of US$2.6 billion.
Underlying profit after tax and amortisation still reached US$3.1 billion, which is the figure worth focusing on because the impairments were non-cash and largely historical.
The forward numbers are what matter here.
CSL is targeting US$400 million of annual cost savings, rising to US$550 million by FY28.
FY27 guidance points to underlying profit growth of around 5%, with a further A$1.1 billion buyback authorised.
On the flipside, the company's dividend was held at US$2.92 per share and net debt sits at 1.8 times EBITDA.
2. Pro Medicus
Pro Medicus is the quality name and remains the expensive one.
The shares trade near $185 against a 52-week high of $321.57, so the derating has been severe.
FY26 revenue rose 22.9% to $261.7 million and underlying net profit climbed 24.1% to $144.7 million.
The company's underlying EBIT margin reached 74.9% and the company remains debt-free with $252.3 million in cash.
Chief executive Dr Sam Hupert was optimistic about the previous year:
We were aiming for 30% increases in EBIT and NPAT, and we exceeded both on a constant currency basis.
The company signed $407 million of new contracts and lifted its dividend 25.5% to 69 cents.
At roughly 75 times earnings the shares are still priced for something close to perfection, though considerably less so than they were twelve months ago.
3. Ramsay Health Care
Ramsay Health Care Ltd (ASX: RHC) is the turnaround story of the three.
FY26 revenue reached $18.6 billion and underlying EBIT rose 11.8% to $1.2 billion.
The EBIT margin improved 30 basis points to 6.2%, which is the number the market had been waiting on.
The full-year dividend lifted 13.8% to 91 cents.
The bigger catalyst is linked to its markets.
Ramsay plans to separate Ramsay Santé, its European business, with a shareholder vote scheduled for 24 November.
Approval would leave behind a simpler, Australian-focused hospital operator with a cleaner balance sheet and a far easier story for investors to value.
What could go wrong with ASX healthcare shares
Each of these stocks carry their own risk.
CSL still has to prove that its cost programme can deliver, and its Vifor division is guided to shrink around 25% in FY27.
Pro Medicus depends on continued contract wins in a US market where it already holds meaningful share.
Then on the other hand, Ramsay's separation still requires a shareholder vote in November, and demergers routinely take longer and cost more than the initial timetable suggests.
Foolish takeaway
Of these three ASX healthcare shares, CSL offers the clearest difference between price and normalised earnings.
Pro Medicus has the best business and the hardest valuation to defend, whereas Ramsay has the most tangible catalyst and yet the least growth behind it.
A brutal twelve months has left the sector significant cheaper than it was, without making any of these three businesses straightforward to own.
